Alkem Laboratories to acquire assets related to API Dronabinol

From AbbVie Inc., USA

Alkem Laboratories has entered into an asset purchase agreement dated 30 December 2019 with AbbVie Inc., USA for acquisition of certain assets related to the active pharmaceutical ingredient, Dronabinol (Assets) which include domain names and trademarks related to "MARINOL", New Drug Application registration with USFDA for Marinol, logos, patents designs, know how, technical and manufacturing instructions, inventory, manufacturing equipment and such items.

The cost of acquisition includes USD 10 million plus suitable working capital adjustments on closing.

Powered by Capital Market - Live News